http://myeloma-cancer.com Just another WordPress weblog Mon, 09 Jun 2008 15:44:44 +0000 http://backend.userland.com/rss092 en Biologic therapy is a treatment that uses the patient's immune system to fight cancer. Biologic therapy uses substances made by the body or in a laboratory to boost, direct, or restore the body's natural defenses against cancer. This type of multiple myeloma treatment is also called biotherapy, biological therapy, or ... http://myeloma-cancer.com/2008/06/09/multiple-myeloma-biologic-therapy-a-summary/ Despite the yearly fanfare regarding new cancer drugs, the percentage of Americans dying from cancer in 2003 was about the same as it was in1970. But, still conventional doctors can't prescribe alternatives cancer treatments. Six hundred lobbyists paid by pharmaceutical companies are doing their best to make sure that conventional ... http://myeloma-cancer.com/2008/06/09/myeloma-cancer-4/ Science News,  Nov 20, 1999  by N. Seppa Although recently developed drugs have made many cancers survivable, multiple myeloma has resisted scientists' best efforts. The likelihood of a patient withstanding this blood-cell cancer for 5 years remains less than 1 in 3--as it has been for 3 decades. Now, the notorious antinausea ... http://myeloma-cancer.com/2008/06/09/thalidomide-combats-myeloma-blood-cancer/ Multiple myeloma is a cancer of the bone marrow with devastating impact on seniors. It strikes people at a median age of 71 years and can lead to fatigue and anemia, painful lesions, calcium abnormalities, kidney problems and infection caused by immune deficiency, and "bad bones" that literally fall apart ... http://myeloma-cancer.com/2008/06/09/newer-approaches-to-multiple-myeloma-treatment-offer-hope/ Robert C. Kane, Peter F. Bross, Ann T. Farrell, Richard Pazdur Division of Oncology Drug Products, Center for Drug Evaluation and Research, United States Food and Drug Administration, Rockville, Maryland, USA Robert C. Kane, M.D., F.A.C.P., U.S. FDA, HFD-150, 5600 Fishers Lane, Rockville, Maryland 20857, USA. Telephone: 301-594-2473; Fax: 301-594-0499; ... http://myeloma-cancer.com/2008/06/09/us-fda-approval-for-the-treatment-of-multiple-myeloma-progressing-on-prior-therapy/ Angelo Vacca   SDX-101, the etodolac R-enantiomer, is an anti-inflammatory drug with a cytotoxic effect on multiple myeloma cells but not on normal peripheral blood mononuclear cells. The antiproliferative activity of nonsteroidal anti-inflammatory drugs and their potential use as antitumor agents are under scrutiny.1 A starting point is the demonstration that ... http://myeloma-cancer.com/2008/06/09/new-aspects-of-myeloma-management/ Multiple myeloma, a cancer of the plasma cell, is an incurable but treatable disease. While a myeloma diagnosis can be overwhelming, it is important to remember that there are several promising new therapies that are helping patients live longer, healthier lives. The estimated frequency of multiple myeloma is 5-6 new ... http://myeloma-cancer.com/2008/06/09/dangers-of-multiple-myeloma/ Malignant proliferation of cells within the bone marrow that usually occurs during middle age or later and increases in occurrence with age. Myelomas are equally common in males and females and affect any of the marrow-containing bones such as the skull, the flat bones (e.g., ribs, sternum, pelvis, shoulder blades), ... http://myeloma-cancer.com/2008/06/09/multiple-myeloma-or-myelomatosis-or-plasma-cell-myeloma-pathology/ Analyzing data of 125 multiple myeloma patients, the authors found a 40-fold increased tumor incidence among the patients and their first-degree relatives as compared to the average population. These tumors were the same as those usually found among Hungarians. There was no difference as to the patient's blood group antigens ... http://myeloma-cancer.com/2008/06/09/increased-risk-for-cancer-in-multiple-myeloma-patients-and-their-first-degree-relatives/ Multiple myeloma (MM) is an incurable heematologic cancer responsible for 2% of cancerrelated deaths. Preclinical studies have underlined the significance of the bone marrow milieu in promoting tumour cell growth, survival, progression and the development of drug resistance. MM has emerged as a novel paradigm for cancer therapy since targeting ... http://myeloma-cancer.com/2008/06/09/myeloma-cancer-3/